WO2018183494A8 - Cd19-targeting antibody-drug conjugates - Google Patents
Cd19-targeting antibody-drug conjugates Download PDFInfo
- Publication number
- WO2018183494A8 WO2018183494A8 PCT/US2018/024840 US2018024840W WO2018183494A8 WO 2018183494 A8 WO2018183494 A8 WO 2018183494A8 US 2018024840 W US2018024840 W US 2018024840W WO 2018183494 A8 WO2018183494 A8 WO 2018183494A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug conjugates
- targeting antibody
- antibody
- targeting
- directed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention is directed to anti-CD19 antibody-drug conjugates and their use for the treatment of B-cell malignancies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480217P | 2017-03-31 | 2017-03-31 | |
| US62/480,217 | 2017-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2018183494A1 WO2018183494A1 (en) | 2018-10-04 |
| WO2018183494A8 true WO2018183494A8 (en) | 2018-12-27 |
Family
ID=62025968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2018/024840 Ceased WO2018183494A1 (en) | 2017-03-31 | 2018-03-28 | Cd19-targeting antibody-drug conjugates |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018183494A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022017595A2 (en) * | 2020-03-03 | 2022-10-18 | Systimmune Inc | ANTI-CD19 ANTIBODIES AND METHODS OF USE AND MANUFACTURE THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58620B1 (en) | 2011-02-15 | 2019-05-31 | Immunogen Inc | Methods of preparation of conjugates |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| BR112016026730A2 (en) * | 2014-05-20 | 2017-12-12 | Immunogen Inc | methods of characterization and treatment of acute myeloid leukemia |
| PE20170775A1 (en) | 2014-09-03 | 2017-07-04 | Immunogen Inc | CYTOTOXIC BENZODIAZEPINE DERIVATIVES |
| CA2957964A1 (en) * | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| JP6843080B2 (en) | 2015-06-29 | 2021-03-17 | イミュノジェン・インコーポレーテッド | Cysteine-modified antibody complex |
-
2018
- 2018-03-28 WO PCT/US2018/024840 patent/WO2018183494A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018183494A1 (en) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018112365A3 (en) | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii | |
| WO2016094837A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
| IL277854A (en) | Antibody-drug conjugates and their uses for the treatment of cancer | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| WO2017201132A3 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| WO2016134335A3 (en) | Pvrig polypeptides and methods of treatment | |
| MX2023010501A (en) | Dantrolene prodrugs and methods of their use. | |
| MX2020006596A (en) | Hydroxyisoxazolines and derivatives thereof. | |
| MX2020003219A (en) | Antibodies having specificity for btn2 and uses thereof. | |
| MX2022002699A (en) | Lurbinectedin in the treatment of malignant mesothelioma. | |
| MX2020001632A (en) | Compositions comprising bacterial strains. | |
| IL279609A (en) | Bifunctional compositions for the treatment of cancer | |
| ZA201907487B (en) | Compositions and treatment procedures for the treatment of pathogenic infections | |
| IL280587B (en) | Flurocytidine derivatives and its composition for the treatment of cancer | |
| WO2018237010A3 (en) | Vaccine compositions and methods of using the same | |
| WO2018183494A8 (en) | Cd19-targeting antibody-drug conjugates | |
| SG11202000612TA (en) | Methods and compositions for the treatment of melanoma | |
| MY182818A (en) | Compositions for the treatment of fibrosis and fibrosis-related conditions | |
| SG11202000724XA (en) | Methods and compositions for the treatment of cancer | |
| IL280262A (en) | Compositions and methods for the treatment of cancer | |
| WO2019028012A3 (en) | Methods of using pembrolizumab and trebananib | |
| HK40093210A (en) | Methods and compositions for the treatment of cancer | |
| HK40059436A (en) | Herboxidiene antibody-drug conjugates and methods of use | |
| EP3876919A4 (en) | Compositions for the treatment of cancer and other conditions | |
| HK40029034A (en) | Methods and compositions for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18718987 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18718987 Country of ref document: EP Kind code of ref document: A1 |